Skip Navigation

Cardiovascular Research 1998 39(1):242-256; doi:10.1016/S0008-6363(98)00081-9
© 1998 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Zolk, O.
Right arrow Articles by Böhm, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zolk, O.
Right arrow Articles by Böhm, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1998, European Society of Cardiology

Alteration of intracellular Ca2+-handling and receptor regulation in hypertensive cardiac hypertrophy: insights from Ren2-transgenic rats

Oliver Zolk, Markus Flesch, Georg Nickenig, Petra Schnabel and Michael Böhm*

Klinik III für Innere Medizin der Universität zu Köln, Joseph-Stelzmann-Straße 9, 50924 Cologne, Germany

* Corresponding author. Tel.: +49-221-4786207; Fax: +49-221-4786550.

Abnormal intracellular Ca2+-handling appears to be a major cause of systolic and diastolic dysfunction in animals and humans with cardiac hypertrophy due to pressure overload and heart failure. However, the precise mechanisms which cause alteration of Ca2+-handling remain unclear. Several lines of evidence suggest that activation of neurohormonal systems may play a central role. In particular, widespread awareness of the importance of the renin–angiotensin system (RAS) has occurred since experimental and clinical studies have detailed the efficacy of angiotensin-converting enzyme inhibitors in reducing morbidity and mortality in patients with left ventricular dysfunction. To evaluate in vivo the role of activated RAS in the regulation of (a) cardiac receptor expression and signal transduction mechanisms and (b) Ca2+ homeostasis, transgenic TG(mREN2)27 rats harbouring the murine renin Ren2d gene were chosen. These animals develop fulminant hypertension and cardiac hypertrophy at an early age despite low levels of renin in the plasma. High expression of the transgene in the vasculature and the heart is associated with increased local formation of angiotensin II. In the Ren2-transgenic model alterations of β-adrenergic neuroeffector mechanisms, Ca2+-handling and {alpha}-adrenergic signal transduction are observed which are very similar to those observed in the myocardium of patients with end-stage heart failure. Moreover, treatment with specific inhibitors of the RAS, such as angiotensin-converting enzyme inhibitors or angiotensin II-receptor antagonists, largely reversed these defects. Studies on TG(mREN2)27 rats may provide new insights into the pathogenesis of hypertensive heart disease and mechanisms which promote disease progression to end-stage heart failure and also may have important implications with regard to therapeutics of heart failure in man.

KEYWORDS Ca2+-handling proteins; TG(mREN2)27 rat; Renin–angiotensin system; Cardiac hypertrophy; Heart failure; β-adrenergic signal transduction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.